< Back to latest news & events

Event

LSPN North America Fall 2024

October 2024

HGF are proud to be platinum sponsors of LSPN North America Fall 2024.

This year’s event will be held in San Francisco on Tuesday 15th and Wednesday 16th of October 2024. This industry-leading event presents an unrivalled gathering of in-house patent counsel from leading pharmaceutical and biotechnology companies. LSPN provides an extensive platform for the most innovative patent holders in the industry to address the challenges they face and explore solutions.

Our Head of Chemistry, Andrew Wells will be speaking on the session ‘EU Clinical Trials Regulations – IP Considerations’ and Head of Life Sciences, Kate Taylor and Partner Mike Nelson will also be hosting a roundtable session on ‘Navigating Clinical Trial Disclosure Requirements’.

Click the button below to find out more.

FIND OUT MORE

Attendees

Andrew
Wells

Partner & Head of Chemistry

Kate
Taylor

Partner & Head of Life Sciences

Michael
Nelson

Partner & European and UK Patent Attorney

Latest updates

The FoodTech Series #1 | Multi-parameter claims, examples outside the scope of the claims: when improvement occurs and evidence becomes easier to demonstrate

            The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they ruled on an opposition …

Read article

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article
See all updates